Overview

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease

Status:
RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.
Phase:
PHASE1
Details
Lead Sponsor:
Nuwacell Biotechnologies Co., Ltd.